Company Analysis
Sign in

Creative Medical Technology Holdings, Inc. (CELZ)

Nasdaq: CELZ · Biological Products, (No Diagnostic Substances) · Phoenix, AZ · filing with the SEC since 2002
Full chart Alerts Compare
Grade4.5
◀ Past 5.7● Present 5.0▶ Future 3.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

8 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Creative Medical Technology Holdings, Inc.’s names, not what it holds today.

Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against none in 2024 and 1 in 2023
Applications published
68
12 of them in 2025
Names they are printed under
4
a subsidiary
By yearGrantedApplications published
'09'10'11'17'18'19'20'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Medical technology2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Creative Medical Technologies, Inc. a subsidiary
US, as the owner printed on each patent
4 granted
65 published
BIO DEFENSE a subsidiary
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in KR)
3 granted
0 published
CREATIVE MEDICAL TECHNOLOGIES, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
Stemspine LLC a subsidiary
US, as the owner printed on each patent
1 granted
0 published
Names not counted (1)
BioDefense Inc.
Most of its patents print KR; this name counts in US. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 19, 202512,391,925Prevention and/or treatment of type 1 diabetes by augmentation of myeloid suppressor cell activityMedical technologyCreative Medical Technologies, Inc.
Aug 12, 202512,385,011Treatment of heart failure and/or post infarct pathological remodeling by ex vivo reprogrammed immune cellsMedical technologyCreative Medical Technologies, Inc.
Oct 24, 202311,795,433Generation of autologous immune modulatory cells for treatment of neurological conditionsBiotechnologyCreative Medical Technologies, Inc.
Nov 24, 202010,842,815Perispinal perfusion by administration of T regulatory cells alone or in combination with angiogenic cell therapiesPharmaceuticalsStemspine LLC
Oct 6, 202010,792,310Methods for treatment of premature ovarian failure and ovarian aging using regenerative cellsPharmaceuticalsCreative Medical Technologies, Inc.
May 10, 20117,939,016Article processing apparatus and related methodMedical technologyBIO DEFENSE
Mar 30, 20107,687,045Article processing apparatus and related methodMedical technologyBIO DEFENSE
Mar 24, 20097,507,369Article processing apparatus and related methodsMedical technologyBIO DEFENSE
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 11, 20252025/0282893PREVENTION OF DIABETES BY ENHANCEMENT OF IMMUNE MODULATIONPharmaceuticalsCreative Medical Technologies, Inc.
Sep 11, 20252025/0281543PREVENTION OF AUTOIMMUNE DIABETESPharmaceuticalsCreative Medical Technologies, Inc.
Jul 10, 20252025/0223563Canine Universal Donor Mesenchymal Stem CellsBiotechnologyCreative Medical Technologies, Inc.
Jul 10, 20252025/0222031Treatment of Disc Degeneration using B Regulatory CellsPharmaceuticalsCreative Medical Technologies, Inc.
Jun 19, 20252025/0201350Artificial Intelligence Detection and Treatment of Biological, Chemical and Radiation ExposureComputer technologyCreative Medical Technologies, Inc.
Apr 10, 20252025/0114404Treatment of Lower Back Pain and Disc Degenerative Disease using Inducible Pluripotent Stem Cell Derived Mesenchymal Stem Cells and T Regulatory Cells UtilityMedical technologyCreative Medical Technologies, Inc.
Mar 6, 20252025/0075186In Vitro and In Vivo Generation of Insulin Producing CellsBiotechnologyCreative Medical Technologies, Inc.
Mar 6, 20252025/0075185Orthopedic Regeneration by Inducible Pluripotent Stem Cell Derived Mesenchymal Stem CellsBiotechnologyCreative Medical Technologies, Inc.
Feb 13, 20252025/0049919Prevention of Immunological Rejection Using Mesenchymal Stem Cells and Derivatives ThereofMedical technologyCreative Medical Technologies, Inc.
Feb 13, 20252025/0049853Treatment of Spinal Cord Injury with T regulatory CellsPharmaceuticalsCreative Medical Technologies, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Biotechnology 8 · Medical technology 4 · Computer technology 3 · Other special machines 1 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CELZ · research, not advice